Vascular endothelial growth factors and receptors in colorectal cancer: implications for anti-angiogenic therapy.

2.50
Hdl Handle:
http://hdl.handle.net/10541/72859
Title:
Vascular endothelial growth factors and receptors in colorectal cancer: implications for anti-angiogenic therapy.
Authors:
Duff, Sarah E; Jeziorska, M; Rosa, Daniela D; Kumar, Shant; Haboubi, Najib; Sherlock, David J; O'Dwyer, Sarah T; Jayson, Gordon C ( 0000-0002-8515-8944 )
Abstract:
There are conflicting associations between growth factor expression and clinicopathological variables in colorectal cancer. This study aimed to define the expression of members of the VEGF family and the receptor, VEGFR2, in primary and metastatic sites of colorectal cancer and their relationship to metastatic potential. Thirty colorectal cancers, 12 lymph node metastases and 9 liver metastases were immunostained for VEGF-A, VEGF-C, VEGF-D and VEGFR2. VEGFR2 was expressed by endothelial cells and by the malignant epithelium. VEGF-C and VEGFR2 were co-expressed in the same territory and correlated throughout the primary tumour and in metastatic lymph nodes, but not in liver metastases. Their expression at the invasive tumour edge correlated with expression in metastatic nodes. The benefit of anti-VEGF antibodies might be increased by directing additional therapies against VEGF-C or against the kinase receptors to target redundancy in the system. A component of the therapeutic benefit might be due to a direct anti-tumour effect as well as an anti-angiogenic effect.
Affiliation:
Department of Surgery, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, United Kingdom.
Citation:
Vascular endothelial growth factors and receptors in colorectal cancer: implications for anti-angiogenic therapy. 2006, 42 (1):112-7 Eur. J. Cancer
Journal:
European Journal of Cancer
Issue Date:
Jan-2006
URI:
http://hdl.handle.net/10541/72859
DOI:
10.1016/j.ejca.2005.09.018
PubMed ID:
16321517
Type:
Article
Language:
en
ISSN:
0959-8049
Appears in Collections:
All Christie Publications ; All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorDuff, Sarah E-
dc.contributor.authorJeziorska, M-
dc.contributor.authorRosa, Daniela D-
dc.contributor.authorKumar, Shant-
dc.contributor.authorHaboubi, Najib-
dc.contributor.authorSherlock, David J-
dc.contributor.authorO'Dwyer, Sarah T-
dc.contributor.authorJayson, Gordon C-
dc.date.accessioned2009-07-07T15:35:23Z-
dc.date.available2009-07-07T15:35:23Z-
dc.date.issued2006-01-
dc.identifier.citationVascular endothelial growth factors and receptors in colorectal cancer: implications for anti-angiogenic therapy. 2006, 42 (1):112-7 Eur. J. Canceren
dc.identifier.issn0959-8049-
dc.identifier.pmid16321517-
dc.identifier.doi10.1016/j.ejca.2005.09.018-
dc.identifier.urihttp://hdl.handle.net/10541/72859-
dc.description.abstractThere are conflicting associations between growth factor expression and clinicopathological variables in colorectal cancer. This study aimed to define the expression of members of the VEGF family and the receptor, VEGFR2, in primary and metastatic sites of colorectal cancer and their relationship to metastatic potential. Thirty colorectal cancers, 12 lymph node metastases and 9 liver metastases were immunostained for VEGF-A, VEGF-C, VEGF-D and VEGFR2. VEGFR2 was expressed by endothelial cells and by the malignant epithelium. VEGF-C and VEGFR2 were co-expressed in the same territory and correlated throughout the primary tumour and in metastatic lymph nodes, but not in liver metastases. Their expression at the invasive tumour edge correlated with expression in metastatic nodes. The benefit of anti-VEGF antibodies might be increased by directing additional therapies against VEGF-C or against the kinase receptors to target redundancy in the system. A component of the therapeutic benefit might be due to a direct anti-tumour effect as well as an anti-angiogenic effect.en
dc.language.isoenen
dc.subjectColorectal Canceren
dc.subjectLiver Canceren
dc.subject.meshAged-
dc.subject.meshAged, 80 and over-
dc.subject.meshAngiogenesis Inhibitors-
dc.subject.meshColorectal Neoplasms-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshLiver Neoplasms-
dc.subject.meshLymphatic Metastasis-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshNeovascularization, Pathologic-
dc.subject.meshVascular Endothelial Growth Factor Receptor-2-
dc.subject.meshVascular Endothelial Growth Factors-
dc.titleVascular endothelial growth factors and receptors in colorectal cancer: implications for anti-angiogenic therapy.en
dc.typeArticleen
dc.contributor.departmentDepartment of Surgery, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, United Kingdom.en
dc.identifier.journalEuropean Journal of Canceren
All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.